Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study
- PMID: 15963399
- DOI: 10.1016/j.jacc.2005.01.059
Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study
Abstract
Objectives: The aim of this study was to evaluate the effect of a new treatment for refractory congestive heart failure (CHF) on brain natriuretic peptide (BNP) plasma levels and hydration station.
Background: The study was aimed at evaluating the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) in refractory CHF patients.
Methods: A total of 94 patients (34 women/60 men) with refractory CHF (age 55 to 80 years) were enrolled. They had to have an ejection fraction <35%, serum creatinine <2 mg/dl, blood urea nitrogen <60 mg/dl, a reduced urinary volume, and a low natriuresis (<500 ml/24 h and <60 mEq/24 h, respectively). Patients were divided (double-blind) into two groups: group 1 (18 women/30 men) received an intravenous furosemide (500 to 1,000 mg) plus HSS twice a day in 30 min. Group 2 (16 women/30 men) received an intravenous bolus of furosemide (500 to 1,000 mg/twice a day) alone, for four to six days. At entry, body weight, blood pressure, heart rate, and laboratory parameters were checked during hospitalization; BNP levels were measured on admission, 6 and 30 days after discharge, while on admission and 6 days after, impedance plethysmography was performed. The HSS group received 120 mmol of Na intake versus 80 mmol in non-HSS group. Fluid intake of 1,000 was given to both groups.
Results: The groups were similar for clinical characteristics. A significant increase in daily diuresis and natriuresis was observed in HSS group, p < 0.05. The BNP values showed significant intragroup and intergroup differences, 6 and 30 days after treatment. The patients from the HSS group reached a better hydration state than the non-HSS group after six days. In addition, the HSS group showed a significant reduction in hospitalization time and readmission rate.
Conclusions: Our data show that the HSS group reached dry weight more rapidly, a significantly faster reduction in BNP levels, shorter hospitalization stay, and lower incidence in readmissions in the 30-day study period.
Comment in
-
Torrent or torment from the tubules? Challenge of the cardiorenal connections.J Am Coll Cardiol. 2005 Jun 21;45(12):2004-7. doi: 10.1016/j.jacc.2005.03.028. J Am Coll Cardiol. 2005. PMID: 15963400 No abstract available.
Similar articles
-
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.Am Heart J. 2003 Mar;145(3):459-66. doi: 10.1067/mhj.2003.166. Am Heart J. 2003. PMID: 12660669 Clinical Trial.
-
Troponin I release after intravenous treatment with high furosemide doses plus hypertonic saline solution in decompensated heart failure trial (Tra-HSS-Fur).Am Heart J. 2012 Sep;164(3):351-7. doi: 10.1016/j.ahj.2012.05.025. Epub 2012 Aug 17. Am Heart J. 2012. PMID: 22980301 Clinical Trial.
-
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure.Eur J Heart Fail. 2000 Sep;2(3):305-13. doi: 10.1016/s1388-9842(00)00094-5. Eur J Heart Fail. 2000. PMID: 10938493 Clinical Trial.
-
Efficiency of Hypertonic Saline in the Management of Decompensated Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies.Am J Cardiovasc Drugs. 2021 May;21(3):331-347. doi: 10.1007/s40256-020-00453-7. Epub 2020 Nov 19. Am J Cardiovasc Drugs. 2021. PMID: 33210263
-
Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites.Semin Nephrol. 2011 Nov;31(6):513-22. doi: 10.1016/j.semnephrol.2011.09.006. Semin Nephrol. 2011. PMID: 22099508 Review.
Cited by
-
Effect of Hypertonic Saline 5% on Early Graft Function and Urinary Interleukin 18 and Neutrophil Gelatinase-Associated Lipocalin in Deceased-Donor Kidney Transplantation.Iran J Pharm Res. 2017 Fall;16(4):1583-1592. Iran J Pharm Res. 2017. PMID: 29552067 Free PMC article.
-
Evolving treatment strategies for management of cardiorenal syndrome.Curr Treat Options Cardiovasc Med. 2011 Dec;13(6):556-69. doi: 10.1007/s11936-011-0148-3. Curr Treat Options Cardiovasc Med. 2011. PMID: 21956184
-
Cleavage of osmosensitive transcriptional factor NFAT5 by Coxsackieviral protease 2A promotes viral replication.PLoS Pathog. 2017 Dec 8;13(12):e1006744. doi: 10.1371/journal.ppat.1006744. eCollection 2017 Dec. PLoS Pathog. 2017. PMID: 29220410 Free PMC article.
-
A patient with heart failure and worsening kidney function.Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1790-8. doi: 10.2215/CJN.11601113. Epub 2014 Apr 24. Clin J Am Soc Nephrol. 2014. PMID: 24763864 Free PMC article.
-
Comparison of three diuretic treatment strategies for patients with acute decompensated heart failure.Herz. 2015 Dec;40(8):1115-20. doi: 10.1007/s00059-015-4327-y. Epub 2015 Jul 2. Herz. 2015. PMID: 26135463 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical